Skip to main content
  1. Home
  2. Emerging Tech
  3. Legacy Archives

Barnes & Noble’s Nook Reviewed, Experts Say It Still Has Kinks

Add as a preferred source on Google

NookForget the Kindle, Sony’s readers and iRex—the tech world predicted the Barnes & Noble Nook to be the top dog this year in the e-Reader race. But how do those predictions stack up against the reality of hands-on reviews?

The Barnes & Noble Nook reviews have been pouring in today and so far the reports have been rather mediocre. For all of the hype this eBook reader has received the tech industry was expecting to see fireworks—but instead, the intriguing device left most reviewers a little “underwhelmed.” Most reviews draw the inevitable comparisons to Amazon’s Kindle since it was the first device to bring eBooks into the mainstream.

Recommended Videos

The reviews weren’t bad, there were actually many positive aspects to the Nook reader such as its large eBook library, built-in free wireless data network, Wi-Fi connectivity, and its color touch-screen pad. The major complaint about this device is it can be a little sluggish in booting up and accessing a book. This is natural with all new devices—the Nook has kinks—and those will soon be revised and worked out. But for now, here are what expert reviews have to say about the Nook.


CNET says the Nook is in need of some software updates to improve the navigation features and to speed up browsing—but, they were pleased with the Nook’s lending of e-books and all of Barnes and Noble’s in-store options for its new e-reader.

Check our CNET’s Review of the Nook


Engagdet seems fairly disappointed in the performance they received from the Nook, noting that it was slow and fell “short on delivery.” In contrast, Engadget also praised the Nook for its LendMe feature and thinks that some software revisions will speed things up for future users.

Check out Engadget’s Hands-on Review of the Nook


Gizmodo has a similar take: They said the Nook’s Android software is definitely in need of an update, but they believe these fixes will come fast and that the future looks hopeful for the e-reader.

Check out Gizmodo’s Nook Review

Dena Cassella
Former Digital Trends Contributor
Haole built. O'ahu grown
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more